Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
81,000
Employees81,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
81,000
Employees81,000

PFE Key Statistics

Market cap
145.74B
Market cap145.74B
Price-Earnings ratio
18.25
Price-Earnings ratio18.25
Dividend yield
6.57%
Dividend yield6.57%
Average volume
44.60M
Average volume44.60M
High today
$25.76
High today$25.76
Low today
$25.50
Low today$25.50
Open price
$25.65
Open price$25.65
Volume
30.30M
Volume30.30M
52 Week high
$31.54
52 Week high$31.54
52 Week low
$24.48
52 Week low$24.48

PFE News

Simply Wall St 2d
Pfizer Faces Shareholder Proposals on Religious Discrimination and Executive Pay Limits

is currently dealing with shareholder proposals concerning governance issues such as religious discrimination and executive pay structures, with the company adv...

Pfizer Faces Shareholder Proposals on Religious Discrimination and Executive Pay Limits
Benzinga 3d
Pfizer's Direct-To-Consumer Model Faces Scrutiny From US Senators

In August 2024, Pfizer Inc PFE introduced the PfizerForAll digital platform in collaboration with UpScriptHealth, Alto Pharmacy, and Instacart. In a letter add...

Pfizer's Direct-To-Consumer Model Faces Scrutiny From US Senators
TipRanks 3d
Arvinas price target lowered to $12 from $48 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Arvinas (ARVN) to $12 from $48 and keeps an Equal Weight rating on the shares after the company and partner Pf...

Analyst ratings

54%

of 24 ratings
Buy
41.7%
Hold
54.2%
Sell
4.2%

More PFE News

Seeking Alpha 4d
Arvinas draws Wedbush downgrade after data for Pfizer-partnered cancer drug

Wedbush became the latest brokerage to downgrade Arvinas (NASDAQ:ARVN) on Wednesday after the company posted underwhelming late-stage trial data for vepdegestra...

Arvinas draws Wedbush downgrade after data for Pfizer-partnered cancer drug
Quartz 5d
Lawmakers demand answers from RFK Jr. over Trump dinners with pharma execs

Three U.S. senators are urging Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. to disclose details about several private dinners he attended wit...

Benzinga 5d
Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial

Arvinas, Inc. ARVN and Pfizer Inc. PFE released topline results from the Phase 3 VERITAC-2 trial evaluating vepdegestrant monotherapy versus fulvestrant in adul...

Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial
TipRanks 5d
Arvinas, Pfizer announce VERITAC-2 achieved primary endpoint in Phase 3 trial

Arvinas (ARVN) and Pfizer (PFE) announced topline results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus fulvestrant in a...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.